CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 113 enrolled
Drug / intervention
Imlunestrant +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05444556
NCT05444556Phase 1Completed
CompareCT.gov

The Effect of Imlunestrant on CYP2C8, CYP2C19, CYP2D6, P-gp, and BCRP Activity and the Effect of P-gp Inhibition on Imlunestrant Pharmacokinetics in Healthy Women of Non-childbearing Potential

Eli Lilly and Company·interventional·Posted Jul 6, 2022·Updated Dec 12, 2025

In Brief

A Phase 1 clinical trial evaluating Imlunestrant, Repaglinide, and 5 other interventions for Healthy. Completed, enrolled 113 participants across 3 sites.

Detailed Summary

The main purpose of this study is to evaluate the effect of imlunestrant on repaglinide, omeprazole and dextromethorphan, and rosuvastatin and digoxin. The study will also investigate the effect of quinidine on imlunestrant in female healthy participants of non-childbearing potential. The safety and tolerability of imlunestrant will be investigated in female healthy participants of non-childbearing potential. The study will last approximately up to 32 days for each participant excluding the screening period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedJul 6, 2022
Enrollment StartJul 7, 2022
Primary CompletionNov 2, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 4.0 years ago

Interventions

Imlunestrantdrug

Administered orally.

Repaglinidedrug

Administered orally.

Omeprazoledrug

Administered orally.

Dextromethorphandrug

Administered orally.

Quinidinedrug

Administered orally.

Rosuvastatindrug

Administered orally.

Digoxindrug

Administered orally.